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Abstract 
The development of antiretroviral therapy has given a new hope for people living with acquired 
immuno deficiency syndrome.  In the face of increased disease burden due to HIV the global 
and political commitment towards controlling the pandemic has received renewed thrust in 
recent times.  The Government of India has initiated antiretroviral treatment as a part of 
national public health programme in the six high-prevalence states.  The aim of the paper is to 
provide the programme planners and other stakeholders, information about the impact of 
initiating antiretroviral therapy programme in the country.  The paper discusses the global 
commitment towards fighting the disease in the light of the development in affordability and 
accessibility of antiretroviral drugs therapy.  The paper highlights the importance of 
infrastructure and logistic requirement for developing a comprehensive treatment programme 
for the affected population in India.  Finally, the paper has drawn broad financial implications of 
the antiretroviral therapy under different treatment scenarios.  The estimated financial 
requirement for treatment vary from Rs. 92 crores per annum if focusing on 400,000 HIV/AIDs 
cases to identify patients requiring ARV Therapy to 1008 crores per annum if all 4 million 
patients are screened for coverage.  Against this NACO has allocated total of Rs. 113 crores for 
treatment part of the proposed intervention. Even under the most conservative estimate 
achieving the treatment target in India with the proposed programme budget will be a 
challenging task.    3
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1.  Introduction 
The allocation of resources assumes greater complexity in health sector interventions because of 
lack of cost-effectiveness measures.  Also, the allocation experiences are constrained by several 
complexities arising out of ethical, legal and human rights issues.  The HIV/AIDS programme, 
in particular, is confronted with these issues in serious way.  To spend on prevention or 
treatment or research – is a dilemma which the programme planners are facing while developing 
financial plans for AIDS control programme.  Given the limited financial resources the question 
of cost-effectiveness of prevention and treatment interventions are important.  How much funds 
can be utilised for treatment by diverting resources from prevention activities without adversely 
affecting the prevalence, particularly when there is no cure or vaccine and “prevention is still the 
only cure for HIV/AIDS”. 
Some of these questions have been discussed at different forums, but it has assumed particular 
attention because of recent round of negotiation on anti-retroviral (ARV) drugs, making it 
around 10 times cheaper to earlier drug prices.  The trade-offs on cost front has eased 
significantly.  In view of these developments and declaring non-availability of drugs to the AIDS 
affected cases as a global emergency, World Health Organisation recently came out with a 
strategy to reach out to 3 million people by 2005, mostly in the severely affected African 
countries with ARV drugs.  The Government of India too has already initiated programme 
intervention to make available treatment with High Active Antiretroviral Therapy (HAART) to 
the 6 severely affected states of India.  
The drug price is not the only component in cost of treatment interventions.  Regular laboratory 
and clinical check-up for the patient, need to continue the drugs for life-time,  side-effects of the 
drugs, resistance to drugs and ensuring continual treatment of the patient are some of the key 
issues in HIV treatment for which there is a requirement for massive mobilisation of health 
infrastructure, human skills and overall a coherent strategy.    4
The objective of this paper is to address financing issue in the proposed HIV/AIDS 
intervention of providing anti-retroviral drugs to selected regions in India.  The paper will briefly 
discuss the epidemiology of HIV/AIDS in India and how India has geared itself to respond to 
the challenge.  A brief review of pros and cons of prevention and treatment is presented.  In 
reviewing the data, the paper draws from examples of how the world has geared itself to deal 
with the problem.  Towards the end of the paper we make an attempt to analyse the financial 
implications of the strategy of the National AIDS Control Organisation (NACO) to initiate 
antiretroviral therapy programme in India.  The last section of this paper attempts to estimate 
the cost of implementing antiretroviral therapy programme in India. 
2.  HIV/AIDS status in India 
There is a global rise in political commitment to combat the pandemic.  The Global Fund to 
fight AIDS, TB and Malaria has approved a total of US $2 billion over two years to 224 
programmes in 121 countries with disbursement currently amounting to US $245 million 
(Global Fund 2004).
  The World Bank is one of the largest sources of financing in the United 
Nations system for HIV/AIDS programmes.  In the last five years, the Bank has committed US 
$1.5 billion through grants, loans and credits to programmes to fight HIV/AIDS.  This also 
includes support to local authorities and nongovernmental organisations. Besides, several 
bilateral and multi-lateral agencies are contributing resources to this sector.  Recently WHO has 
initiated a programme to treat 3 million people affected by AIDS by 2005.  UNAIDS has 
estimated that the world will need about $10 billion per annum to mount an effective and 
comprehensive response in low and middle income countries.  Currently the total amount of 
fund that is available to fight the problem is only to the tune of $ 4.7 billion including resources 
from Global Fund to Fight AIDS, TB and Malaria and the World Bank. 
According to estimates around 4.6 million individuals, (slightly less than 1 percent of the adult 
population) are infected with HIV.  According to official estimates by NACO, cumulative AIDS 
cases in India till March 2004 are 68809.  The number of people living with the virus is fast 
approaching 5 million.  These figures, although questioned to be gross under-estimation at 
different forums is enough to press the alarm bell as we are now having the second largest 
number of people living with the HIV/AIDS, after South Africa.    5
Given India's large population, HIV/AIDS can assume threatening proportions.  For example, 
by a mere 0.1 percent increase in the prevalence rate, the number of adults living with 
HIV/AIDS will increase by over half a million persons.  According to World Bank estimates the 
epidemic has already advanced into the generalised state (with an adult population of more than 
1 percent) in six states and India accounts for 10 per cent of global HIV burden and 65 per cent 
of that in South and South East Asia (World Bank 2003).  The major route of transmission is 
through sexual contact.  Another risk group is injecting drug users in the early years.  There are 
threats that this disease is gradually spreading from the high-risk groups to the general 
population through the “bridge population”.  The spread to the general population is borne out 
by rising number of cases among pregnant women and their infants.  The growing prevalence of 
HIV/AIDS poses serious social and economic threats and need effective policy response. 
In response to the growing prevalence of HIV/AIDS cases, the Government of India in 1987 
established national AIDS control programme with the primary objective of monitoring HIV 
infection rates among risk population in a few major cities.  The first funding commitment of 
$99.6 million to the Indian National AIDS Control Project Phase-I (1992-1997) was finalised in 
1992.  The project was funded by an $84 million International Development Association (IDA) 
credit of World Bank and supplemented by WHO/GPA co-financing of $1.5 million and a 
planned government contribution of $14.1 million.  The project objective was to contain the 
spread of HIV by initiating a major effort to prevent HIV transmission. National AIDS Control 
Organisation (NACO) was established as a semi-autonomous body under the MOHFW and 
Sate AIDS control cell were established in all states.  
The second phase of the project with total financial commitment of $229.8 million (Rs. 1155 
crore) got finalised in 1998.  The World Bank contributed $191 million and the rest coming 
from Government of India.  At the same time the government of India also initiated two other 
projects with the support of US assisted AVERT in Maharashtra for Rs.166 crores and DFID in 
Andhra Pradesh, Orissa, Kerala and Gujarat for Rs.104 crores.  These funding commitments 
marked the Phase II of the National AIDS Control Programme (1999-204) as a 100 per cent 
Centrally Sponsored Schemes.  The approved year-wise phasing of the budget and expenditure 
incurred in the programme is given below:   6
Allocation and Expenditure (Rupees in crores) 
Outlay   Year 
  World Bank, GoI  USAID  DFID  Total   Expenditure*
1999-2000   154.5  43.6  12.63  201.73   135.25
2000-2001   270.1  28.5  18.69  317.29   179.64
2001-2002   257.9  28.5  22.22  308.62   228.49
2002-2003   193.1  28.5  22.14  243.74   240.00
2003-2004   198.0  25.1  28.31  251.42   NA
2004-2005   81.40  11.80  --  93.20   NA
Total  1155.0  166.0  104.0  1425.00   783.38
*Source: Lok Sabha unstarred question no. 3275, dated 04.02.2004(India Stat) 
The component- wise allocation of this amount is as follows:   
Component Allocation of WB & GOI funding 
 (in crores of rupees) 
Targeted interventions for groups at high risk   265.6 
Preventive interventions for the general community  389.1 
Low cost AIDS care  163.3 
Institutional strengthening   286.5 
Inter-sectoral collaboration   50.5 
Total (1999-2005)  1155.0 
Source: NACO website 
 
The programme implementation was through the various AIDS control societies specially 
constituted for the implementation of this programme.  The Planning Commission of India had 
also approved an outlay of Rs. 1270 crores for implementation of the HIV/AIDS Control 
Programme during the 10
th Five Year Plan Period as against a total budgetary outlay of Rs. 9253 
cores for the Ministry of Health and Family Welfare (Planning Commission).  Besides several 
bilateral and multi-lateral agencies like Bill & Melinda Gates Foundation and Global fund to 
fight AIDS, TB and Malaria has also ensured support HIV/AIDS intervention in India. 
3.  Anti-retroviral Drugs and HIV 
With no vaccines for HIV round the corner, antiretroviral therapy is considered to be the only 
option available to contain the disease progression once it affects the human body.  The drugs 
are generally of four classes based on the enzymes the virus requires in order to replicate - 
Protease Inhibitors (PIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-  7
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and fusion inhibitors (Laurence and 
Coffey 2003).  WHO has approved the use of the first three drugs.  The drugs do not cure the 
disease but helps in prolonging the life span and has to be taken throughout the life.  Default in 
taking the medicine results in relapse of the disease and efforts on structured intervention will 
result into limited success.  
Antiretroviral therapy costs remain an important barrier to treatment.  The prohibitive cost of 
the drugs so far hindered many people from taking the medicine or continuing treatment. 
According to estimates, of the 6 million people who currently urgently need antiretroviral 
therapy in developing countries, fewer than 8 per cent are receiving it (WHO 2003). While the 
initial price for an antiretroviral three-drug regimen was about US$ 10,000 per patient per year, 
high-quality generic drug regimens are now available for as less as US$ 140 per person per year.  
Some developing countries have shown good success in their response to HIV/AIDS, 
particularly when it comes to preventing new infections among young people and treatment of 
AIDS cases with antiretroviral therapy.  In Thailand, government determination to enforce 100 
per cent condom use in brothels and to ensure wide access to HIV prevention campaigns 
through schools, mass media, and workplace have been key factors in lowering HIV infection 
rates.  The broad-based campaign has led to an increase in condom use, a reduction in visits to 
sex workers, and a dramatic reduction in HIV infection rates (WHO 2000a).  The Mwanza Trial 
is an example of effectiveness of improved treatment service for sexually transmitted infection 
(STIs) in preventing HIV infection (Grosskurth, Mosha and Todd 1995).  The administration of 
antiretroviral drugs during pregnancy time around delivery has proved to be effective in 
significantly reducing the risk of MTCT (mother to child transmission), mainly among non-
breastfeeding population.  A study in Uganda (WHO 2000b) demonstrated a 47 percent 
reduction in MTCT following the administration of a single dose of nevirapine to the mother at 
the onset of labour and to the baby within 72 hours after birth.  The Brazilian experience of 
providing free Anti-retroviral drug therapy to HIV/AIDS patients has resulted in more than 
60,000 AIDS cases, 90,000 deaths and 358,000 AIDS related hospital admission averted from 
1996 to 2002.  This resulted in a cost savings of more than US$1.1 billion from 1997 to 2001.  
This compounded with savings from ambulatory care and drugs for opportunistic infection rises 
to approximately US$2 billion (Teixeira, Vitória, and Barcarolo 2003).    8
4.  WHO initiative of treating 3 million by 2005 
The lack of antiretroviral treatment has been recognised as a global health emergency.  There is 
significant need to deliver antiretroviral treatment to the millions who need it.  In 2003 
UNAIDS along with Global Fund to fight AIDS, TB and Malaria partnered with WHO to 
develop a strategy of providing treatment to 3 million people of developing countries with High 
Affective Anti-retroviral Treatment (HAART) by 2005.  The reports (WHO/UNAIDS 2003, 
WHO 2002)  has estimated that under optimal condition, 3 million people living in developing 
countries could be provided antiretroviral therapy and access to medical services by the end of 
2005.  The total estimated fund needs for the programme is estimated at minimum of $5.5 
billion by end 2005. 







5.  Prevention vs. treatment: cost-effectiveness analysis 
The question has posed a wide range of debate among programme planners, particularly 
considering the high cost of the drugs and the fact that a person on HAART needs to continue 
it throughout his life time.  A study by Marseille
 2002, on the cost-effectiveness of HIV 
prevention in sub-Saharan Africa and on highly active antiretroviral therapy (HAART) indicates 
that prevention is at least 28 times more cost effective than HAART. Further the study pointed 





































Adjusted Life Year (DALY) as would $55 million spend on prevention. On the other hand, it is 
estimated that a higher percent of 1.5 million people living with HIV in high-income countries 
will lead a productive life as a result of receiving highly active ARV therapy.  In the USA, the 
introduction of triple combination ARV therapy in 1996 led to a decline of 70 per cent in deaths 
because of HIV/AIDS (WHO 2002). In developing countries with access to ARV therapy the 
same profound effects have been documented.  For example in Brazil, AIDS deaths have 
decreased by 73 per cent since the introduction of highly active ARV therapy (Teixeira, Vitória 
and Barcarolo2003).  According to a recent study by researchers from the San Francisco 
Department of Public Health
 (Porco, Martin and Shafer 2004), the introduction and widespread 
use of high active antiretroviral therapy (HAART) for HIV-infected persons in San Francisco in 
the late 1990s reduced their risks of infecting partners by 60 per cent. However, a concurrent 
increase in risk behaviour has been noticed among the study population.  Therefore the 
programme managers have been suggesting an effective strategy which also focused on better 
counselling and various preventive measures along with ARV therapy to reduce the spread of 
virus from the infected person and thus lower the incidence of the disease among the 
community.  Using this argument, the pharmaceutical companies also argue for the strategy of 
both prevention and treatment.  
Notwithstanding all arguments that treatment is far more expensive than prevention, given the 
positive externalities, governments do have a moral responsibility towards providing treatment 
to people living with HIV/AIDS.  This becomes all the more important for number of reasons 
because the anti-retroviral drugs are still not affordable to an average person.  Since the drug has 
to be administered throughout the life, achieving good compliance rates is problematic if the 
costs of treatment are borne by the patient.  The default rates may be high because of financing 
burden.  It is also expected that the availability of therapy will be a good incentive for more and 
more people to disclose their HIV status and come forward for screening and treatment.  Last 
but not the least, those on regular HAART will be carrying lower viral load in their blood stream 
and hence less prone to transmit the virus to others.  Over and above the various gains of 
providing treatment with HAART will be in terms of: delayed clinical progression of the disease, 
improvement in quality of life, reduction in the number of orphans in the population, reduction 
in the people being hospitalisation because of HIV/AIDS, reduction in HIV transmission,   10
reduction in opportunistic infection (OI) and return in productive life by people as a result of 
the above.  
6.  Are we adequately prepared for the task? 
Last year the government of India announced a plan to cover 100,000 AIDS cases in India and 
provide treatment on structured anti-retroviral therapy.  The target to achieve this goal is 2005.  
In addition to this the programme envisages to provide treatment to additional of 15 to 20 per 
cent of AIDS cases each year, thereafter, for a period of five years.  Initially the programme will 
be implemented in six high prevalent states with a funding commitment of Rs. 200 crores for the 
infrastructure needed to implement this programme.  Of this amount Rs. 113 crores is meant for 
medicines and Rs. 87 crores for providing infrastructure to screen people for HIV/AIDS 
infection (NACO 2003).  Regarding the provision of drugs, the programme aims to focus on 
three categories of patients viz., (i) sero-positive mothers who have participated in the PPTCT 
programme; (ii) seropositive children below the age of 15 years; and (iii) people with AIDS who 
seek treatment in government hospitals (NACO 2003).  According to the plan, patients will be 
provided a cocktail of three drugs - Lamivudine and Nevirapin with either Stavudine, 
Zidovudine or Efavirenz - to be taken twice daily.  This task would involve addressing the 
following key elements.  
Need to find the number of people requiring HAART: One of the important tasks in 
implementing the programme is to identify the cases that would be covered by HAART.  For 
this purpose epidemiologists and health planners use the cumulative number of AIDS cases 
as the reference point.  However, it is quite evident that the definitions of AIDS cases and 
those who should be covered by HAART vary from country to country.  The criteria for 
defining the number of cases has implications for who should necessarily or directly be 
having need for antiretroviral therapy.  There is, however, some agreement on that the 
definition based on CD4 cell count (i.e., number of viral copies) may be an effective way to 
define the need for ARV treatment than the number of cases (cumulative) or total estimate of 
HIV infected individuals.  It is important to have better estimates of the total number of 
individuals who actually need antiretroviral therapy in order to plan the budgets to provide 
treatment through anti-retroviral therapy.  The official figure of NACO on estimated HIV   11
infected cases and actual number of people with full blown AIDS is questioned at various 
levels as under-reported.  However, there is no reliable estimate by any agencies/organisation 
about the exact number of AIDS cases on the basis of CD4 cell count who actually need to 
initiate antiretroviral therapy in order to live a productive life.  
Monitoring the risk:  For effective implementation of ARV therapy it is important to monitor 
risk.  For this purpose there is a need to establish adequate chain of laboratories to monitor CD4 
cell count and viral load every 3-6 months in people under clinical care for HIV infection.  In 
Brazil, for example, where anti-retroviral therapy is provided free as a part of national health 
programme to 1 lakh of its population, the government has created a chain of laboratories in 
order to screen 4 lakh people living with HIV/AIDS for their viral load count. The draft policy 
document of NACO does not specify any mechanism to create laboratory chain to screen the 
people living with HIV/AIDS.  The programme document also does not talk about any formal 
supervisory mechanism for implementation of the programme.  
Although the programme guidelines have made an attempt to justify that due to higher 
frequency of administration of the drug therapy, it might not be possible to imitate DOTS type 
strategy in HIV treatment, however, some degree of supervision is essential for implementation 
of such programme which has a higher risk of side-effects and non-compliance resulting in 
negative notion towards the programme.  Another aspect to look at the scheme of providing 
ART to AIDS patients is supply-chain management.  The importance of supply chain 
management can best be explained from the experience of pre and post Revised National 
Tuberculosis programme (RNTCP) in India.  Proper and timely accessibility of the multiple 
drugs for Tuberculosis has led to treatment adherence in post RNTCP era, while failure to do so 
in the pre-RNTCP period lead to lot of treatment non-compliance (Sahu, Reuben and Chauhan 
2003).  The point of reference is sited here because anti-retroviral therapy also involves a 
cocktail of multiple drug regimens.  The NACO programme document states that the 
overwhelming short term priority is for first-line regimens which will facilitate the scaling up of 
treatment. Second-line treatment is not a priority in the short-term. 
Managing HIV co-infection:  The programme needs to have strategies to cope with HIV co-
infections among patients undergoing anti-retroviral therapy.  Although, the programme   12
document has mentioned about management of HIV co-infections, it is not explicitly 
mentioned whether the same will be provided as free to patients undergoing antiretroviral 
therapy.  
Financial planning:  In order to assess the total funds requirements to implement programme 
and ensure that drugs supply is maintained, the programme will require developing a good 
financial system to forecast funds requirements over the period.  As discussed in previous 
sections that the treatment has to life-long and need sound system of forecasting the 
requirements to implement the programme effectively.  This becomes all the more important 
because, cost for the programme does not only involve cost for the drugs, but also cost for 
routine diagnosis of the patients, cost of mobilising human resources and health system 
machinery and cost of opportunistic infections averted  and cost of benefits gained by each HIV 
infections averted.  With a proper financial system it would be easy to establish cost-
effectiveness of the programme. It can assess the risk better and can evaluate the momentum to 
enhance capacities of the public health systems for rational management of the HIV infected in 
a sustainable manner.  
Treatment effort has to be adequately complemented by prevention activities because of the risk 
of clients discontinuing condom use and ignoring various preventive approaches. 
7.  Factors determining financial requirements 
For calculating the cost of the programme, we need to understand the natural history of the 
disease progression, life time risk of patient to contract the disease, incidence of Opportunistic 
Infections relative to CD4 cell count in the patient and survival analysis thereof.  The median 
interval from HIV infection to the development of severe immune deficiency appears to be 
similar in all populations (i.e., in developed and developing countries) and is estimated to be 
about 7-8 years.  However, there is a consensus that the survival period from the development 
of severe immune deficiency to death is much shorter in most developing countries compared 
with developed countries, where the advent of HAART therapy has significantly increased 
survival of patients with moderate immune deficiency related to their HIV infection.  A recent 
review of cohort studies in Uganda, Thailand and Haiti indicates that the median interval from 
HIV infection to death is 9 years (UNAIDS 2003).  It has been found that the survival time after   13
onset of AIDS related illnesses is also variable.  Prior to the development of effective ARV 
therapy, average survival time was about 2 to 4 years in most developed countries and about 6 
months or less in developing countries.  The proportion of HIV infected persons who, in the 
absence of ARV treatment, will ultimately develop AIDS has been estimated to be over 90 per 
cent.  In the absence of effective ARV treatment, the AIDS case-fatality rate is very high.  Most 
(80-90 per cent) patients in developed countries die within 2-4 years after the diagnosis of AIDS 
is made.  It should be noted that most of the information on effects are from developed country 
context.  It is well known that the risks and its effects vary from country to country.  In India the 
relation between CD4 cell count and risk of developing Opportunistic Infections and median 
time of survival thereof has been investigated by YRG Care, an NGO working in southern 
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Figure1: HIV natural history (based on YRG Care study) 
Figure 1 depicts the natural history of HIV/AIDS in terms of the number of T-helper 
lymphocytes per cubic millimetre of blood, known as CD4 cell count.  The figure depicts the 
transition of an HIV infected person from the period of transition to the period of developing 
full blown symptoms of AIDS defining illness corresponding to their CD4 cell count.  The   14
AIDS defining opportunistic infections listed here are the common opportunistic infections 
found in the Indian sub-continent.  However, the figure has to be interpreted with much care. 
The median CD4 cell count depicted in the figure cannot be taken as standardised.  For example 
the pulmonary tuberculosis which was reported at median CD4 cell count of 111 cells/µL (from 
the cohort study of 594 cases in YRG Care, India) is reported at median CD4 cell count of 6 
cells/µL in a similar study in a cohort study at Switzerland (Bruno et.al.1999). The difference 
may be attributed to the differential disease pattern based on geographical and epidemiological 
variation, however the details for the reason is not discussed here.  We have referred the Indian 
study data, since our major objective is to assess the cost of treatment intervention in India.  The 
YRG Care study has tried to find out through univariate analysis, the median duration of 
survival for patients who presented with or developed opportunistic infections as compared to 
those who did not.  The study result showed that various OIs (such as pulmonary tuberculosis, 
oropharyngeal candidiasis, P. carinii pneumonia, cryptococcal meningitis and CNS 
toxoplasmosis) were associated with increased risk of death in a patient.  Further the study 
found that person who had more than one opportunistic infection were 2.6 times more likely to 
die than were those who did not. 
Financial requirements for antiretroviral therapy  
According to NACO statistics the cumulative reported number of AIDS cases in India as on 
March 2004 is 68809.  The ARV therapy programme has proposed to include 100,000 persons 
on antiretroviral drugs by 2005.  There are questions regarding these numbers as well as whether 
we have provided adequate funding for this intervention.  Since, we do not have accurate data 
on the exact number of cases we base our projections of financial requirements based on two 
scenarios.    
Scenario 1 
We assume that the cost will be incurred in screening the entire estimated HIV affected cases 
and then identifying and placing 100,000 population with CD4 cell count less than 200 cells/µL 
or symptomatic patients urgently requiring treatment under HAART regimen.  This scenario is 
further divided into two cases: (i) where screening is done in the six high-prevalence states of 
India and the policy proposes to implement the treatment programme and (ii) if screening is 
done throughout the country to assess the actual number of cases requiring treatment.  The   15
second option of Scenario 1 is more appropriate one, but there would be many practical 
difficulties in implementing this intervention.  This is because the sentinel surveillance data of 
estimating the HIV cases gives the crude estimate of HIV affected cases and not the absolute 
identification of the infected cases.  
Scenario 2 
WHO has estimated that about 10 per cent of HIV cases estimated may need ARV therapy 
(WHO 2002).   The antiretroviral therapy programme of Brazil has a network of 138 
laboratories which screened about 400,000 risk cases and then focused on those needing  ARV 
therapy.  We develop second scenario based on this point.  We also assume that facilities will be 
set up for screening of 400,000 high-risk cases per year and then placing 100,000 cases who have 
progressed to sever symptomatic phase or asymptomatic cases with CD4 cell count less than 200 
cells/µL on the therapy.  
In making our financial projections under both the scenarios we make the following 
assumptions: 
  The patients will continue treatment effectively under first line therapy throughout their life 
span.  The cost of first line therapy is taken as the Clinton Foundation agreed price $140
1 
and in rupee terms as Rs. 6790 per person per annum.  
  For calculating the cost of CD4 cell count we use two price scenarios: one, the current 
market price at Rs. 1200 per test and second, Clinton Foundation agreed price $5 (in rupee 
terms Rs. 243).  This information is taken from Wall Street Journal (January 14, 2004). 
  As per recommended guidelines the HIV infected person CD4 cell count test will be 
repeated twice every year in order to monitor the progress and for the patients under 
treatment the test will be repeated quarterly to monitor the progress of treatment. 
  The estimated HIV infected cases in Scenario 1 for the six high-prevalence states and for 
Scenario 2 all Indian states combined is taken from the official NACO estimate for 2002. 
                                                 
1  Exchange rate used in the paper is $1 = Rs. 48.50   16
Estimates  
Figure 2 gives the summarised financial requirements under two different scenarios.  The details 
of these calculations are given in Table 1.  Scenario 1 (six high-prevalence states), the annual 
combined cost of screening, cost of anti-retroviral therapy and monitoring the progress of 
patients come to approximately Rs. 714 crore per annum under assumption of CD4 cell count 
test at Rs. 1200 per test and Rs. 198 crore under assumption of CD4 cell count test at Rs. 243 
per test.  The corresponding projections, if the entire Indian HIV population are screened would 
be Rs. 1008 crore and Rs. 258 crore.  
Scenario 2 assumes that there would be adequate facilities and infrastructure by way of chain of 
laboratories for screening of 400,000 HIV infected case and identifying 100,000 cases under 
structure antiretroviral therapy.  The annual cost will come to Rs. 187 crore under the 
presumption of CD4 cell count test at Rs. 1200 per test and Rs. 92 crore under the presumption 
that CD4 cell count test will be available at Rs. 1200 per test.  Table 1 provides the details of 
these computations under each scenario and component-wise under two price scenarios.  Figure 
2 provides summary of these financial requirements. 
Scenario 1  Scenario 2            Scenario 
 




Screening of 400,000 
high-risk cases 
Market Price of CD4 cell count 
(Rs. 1200 per  test) 
7141 10081  1879 
Clinton Foundation  agreed price 
of CD4 cell count  (Rs. 243 per 
test) 
1988 2583  922 
Figure 2: Per annum cost (in millions of rupees) of treating 100,000 population 
In above calculations we have not included the cost of treating Opportunistic Infection. 
However, as plotted in Figure 1, the median CD4 cell count for various Opportunistic 
Infections, it is evident that a person with CD4 cell count less than 200 cells/µL, is at a high risk 
of contracting Opportunistic Infections.  Moreover, potent antiretroviral therapy is known to 
reduce the incidence of opportunistic infection by about 85 per cent.   
In addition to these costs, following items need to be included to develop a comprehensive cost 
calculation:   17
  Establishment and up-gradation cost of existing facilities. 
  Additional human resources and supervisory cost required for the purpose 
  Alternative therapy in case of drug failure or drug resistance and cost of treatment for 
opportunistic infection. 
Cost of various other tests for example, Elisa and Western Blot test are done for screening of 
the HIV infected tests and viral load count (optional) for monitoring of patients under 
treatment.  There are several other tests to find out drug compliance and tests for opportunistic 
infections during the treatment period.  These tests were not included in this cost calculation. 
The cost calculation presented here are only for one year.  Additional cost of the therapy is not 
included in the calculation.  This cost arises because new cases may get included in the treatment 
category.  Ideally the cost calculation should consists of cost per person year lived after adjusting 
for mortality rates and because of which some cases will get excluded from treatment.  In order 
to do these calculations we would need information on median life survived by a patient on 
antiretroviral therapy as adjusted against his/her viral load.  The YRG Care study shows the 
median duration of survival for subjects who initiated antiretroviral therapy when their CD4 
lymphocyte counts were <200 cells/µL was 45 months, as against those with comparable CD4 
lymphocyte counts who did not receive antiretroviral therapy, the median duration of survival 
was only 33 months.  This figure was different (22 months) in the study of Skiest and Crosby 
(2003).  There is significant variation in the results and geographic region and development 
index seem to influence these results obtained by these studies.  We have not done this 
adjustment in our estimates here.  
8.  Conclusion 
Under most conservative estimates, the annual requirement of funds for ARV intervention 
works out to be Rs. 92 crores per annum.  This is based on assumption that infrastructure 
(including testing facilities) would be available to screen at least 400,000 HIV infected cases per 
year and these tests would be done at the cost agreed upon by international companies with the 
Clinton Foundation.  This estimate does not include many other costs associated with treatment 
and human resource mobilisation as mentioned above.  This raises questions on the financial 
feasibility of government’s programme as it has been proposed to allocate total of Rs. 113 crore   18
towards treatment of 100,000 AIDS cases on structured anti-retroviral therapy by the end of 
2005.  Beside financial cost, there are several other management and implementation issues 
pertaining to technical aspect, capacity aspect and public-private partnership issues particularly 
involving NGOs in managing the programme which needs to be addressed in greater detail.  
The financial requirements as estimated are highly sensitive to price assumptions.  In case we do 
not get favourable price the requirements go as high as Rs. 714 crores in six high-prevalence 
states.  The programme implementation strategies need to consider these scenarios.  There is 
also need to learn from our previous experiences.  For example, the financial requirements 
turned out to be significantly different than what was planned in pre DOTS strategy on treating 
Tuberculosis.  Along with the funds requirements for HAART intervention, the programme will 
require funds for preventive interventions as well.  WHO in their cost estimation for reaching 
the target of 3 million with access to antiretroviral therapy by 2005 has indicated that their cost 
estimation includes only those preventive activities required to support the programme directly.  
They do not include scaling up other interventions and health infrastructure given the short time 
frame until 2005.  There is need to carry out detailed exercise on developing proper financial 
plan keeping in view all the budgetary constraints and objectives of the programme.  Various 
scaling-up issues can also be addressed through this exercise.  The implementation of 
programmes will also need high political commitment and support.  The financial planning 
framework should also address the question of spending on prevention and treatment and 
should consider treatment strategy as complementary to prevention strategy.  We also need to 
initiate pilots and develop some understanding of the risks involved in these choices.  In the 
absence of this framework, the programme implementation and policy formulation will remain 
ad-hoc and would be subject to high implementation risk.  
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Table1 
Scenario 1: Screening the entire HIV estimated case and putting  
100000 case with CD4 cell count less than 200 on treatment 
   Six  high 
prevalent state 
All Indian state 
combined 
HIV estimate in 2002  2592498  3817656
Screening cost 
Cost of CD4 cell count at Rs. 1200  
per test @ 2 test per year 
6221995200 9162374400
Cost of CD4 cell count at  
$5~Rs. 243 @ 2 test per year 
1259954028 1855380816
Treatment cost 
Cost of giving first line ARV @ $ 140~Rs. 6790  
per person per year for 100000 person 
679000000 679000000
   
 
Additional Cost of CD4 cell count for the 100000  
patients for 2 extra test per year at Rs. 1200 per test 
240000000 240000000
Additional Cost of CD4 cell count for the 100000  
patients for 2 extra test per year at $5~Rs. 243 per test
48600000 48600000
Total cost 
Cost of screening, providing drugs and monitoring at present CD4 cell testing cost (Rs. 1200)  
In six high prevalent states =Rs. 714,09,95,200 
Cost of screening, providing drugs and monitoring at present CD4 cell testing cost (Rs. 1200) 
 in all over India = Rs. 1008,13,74,400 
Cost of screening and providing drugs and monitoring at agreed CD4 cell testing cost (Rs. 
243) in six high prevalent states = Rs. 198,75,54,028 
Cost of screening and providing drugs and monitoring at agreed CD4 cell testing cost (Rs. 
243) in all over India = Rs. 258,29,80,816 
 
Scenario 2: Screening of 400000 HIV cases through a chain of testing centres for CD4  
cell count and putting 100000 case with CD4 cell count less than 200 on treatment 
Screening cost 
Cost of CD4 cell count at Rs. 1200 per test @ 2 test per annum for 400000 
HIV+ve cases 
960000000
Cost of CD4 cell count at $5~Rs. 243 per test @ 2 test per annum for 
400000 HIV+ve cases 
194400000
Treatment cost 




Additional Cost of CD4 cell count for the 100000 patients for 2 extra test per 
year at Rs. 1200 per test 
240000000
Additional Cost of CD4 cell count for the 100000 patients for 2 extra test per 
year at $5~Rs. 243 per test 
48600000
Total cost 
Cost of screening and providing drugs and monitoring at present CD4 cell testing cost 
(Rs. 1200) = Rs. 187,90,00,000 
Cost of screening and providing drugs and monitoring at present CD4 cell testing cost  
(Rs. 243) = Rs. 92,20,00,000 
   20
References 
1.  Bruno L, et. al. (1999). AIDS-Related Opportunistic Illnesses occurring after Initiation of 
Potent Antiretroviral Therapy. The Swiss HIV Cohort Study JAMA, Vol. 282, No. 23; 
American Medical Association.  
2.  Department of Health and Human Services (2004). Guidelines for using antiretroviral agents 
among HIV-1-infected adults and adolescents. Developed by the panel on clinical practices 
for treatment of HIV Infection. 
3.  Grosskurth H, Mosha F, Todd J (1995). Impact of improved treatment of sexually 
transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 
346: pp. 530-6. 
4.  Global Fund to fight AIDS, Tuberculosis and Malaria, Progress Report, February 2004.  
5.  Kumarswamy N, Solomon S, Flanigan TP, Hemalathan R, Thyagarajan SP (2003). Natural 
History of Human Immonodeficiency Virus Disease in Southern India. Clinical Infectious 
Diseases 36:79-85. 
6.  Laurence P, Coffey S (2003). Overview of Antiretroviral Drugs. University of California San 
Francisco. 
7.  Marseille E, Hofmann PB, Kahn JG (2002). HIV prevention before HAART in sub-Saharan 
Africa. Lancet 5; 359(9320):1851-6. 
8.  NACO (National AIDS Control Organisation) (2003). Programme Implementation 
Guidelines for a phased Scale up of access to Antiretroviral Therapy for People Living with 
HIV/AIDS. 
9.  NACO, Ministry of Health & Family Welfare, Government of India. Programme Financing. 
10. Planning Commission, Government of India, Tenth Five Year Plan. 
11. Porco TC, Martin JN, Shafer K (2004). Decline in HIV infectivity following the introduction 
of highly active antiretroviral therapy, AIDS 18(1):81-88.  
12. Skiest DJ, Crosby C (2003). Survival is prolonged by highly active antiretroviral therapy in 
AIDS patients with primary central nervous system lymphoma, AIDS. Volume 17(12) pp 
1787-1793 
13. Solomon S (2004). AIDS – Current Status and Year Ahead. Expertspeak,  
WebHealthCentre.com  
14. Sahu S, Reuben G, Chauhan LS (2003). Role of WHO Recruited Consultants in Successful 
Implementation and Expansion of the DOTS Programme in India. Journal of the Indian 
Medical Association. 
15. Teixeira PR, Vitória MA, Barcarolo J (2003). The Brazilian Experience in Providing 
Universal Access to Antiretroviral Therapy; International AIDS Economics Network; 
Economics of AIDS and access to HIV/AIDS Care in Developing Countries, Issues and 
Challenges, Chapter 2. 
16. UNAIDS (2003). AIDS Epidemic Update.   21
17. WHO (2000a). Health a key to prosperity: success stories in developing countries -  
Thailand achieves sustained reduction in HIV infection rates. 
18. WHO (2000b). New Data on the Prevention of Mother-to-Child Transmission of HIV and 
their Policy Implications. Inter-agency task team on Mother-to-Child transmission of HIV. 
19. WHO (2002). Scaling Up Antiretroviral Therapy in Resource Limited Settings: Guidelines 
for a Public, Health Approach.  
20. WHO/UNAIDS (2003). Estimated cost to reach the target of 3 million with access to 
antiretroviral therapy by 2005 (“3 by 5”). 
21. World Bank (2003). AIDS Regional Update.  
22. World Bank Operations Evaluation Department (2003). Project Performance Assessment 
Report; India National AIDS Control Project. 